Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Prodromal Parkinson's Disease
NCT05611372Phase 3Withdrawn
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 3, randomised, double-blind trial of rasagiline in Parkinson's disease (PD) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Disease-free survival time at 3 years. Planned start Jan 2023; status: withdrawn.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05611372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611372.